140 results on '"Van Etten B"'
Search Results
2. Potential Predictive Immune and Metabolic Biomarkers of Tumor Microenvironment Regarding Pathological and Clinical Response in Esophageal Cancer After Neoadjuvant Chemoradiotherapy: A Systematic Review
- Author
-
Wang, H. H., Steffens, E. N., Kats-Ugurlu, G., van Etten, B., Burgerhof, J. G. M., Hospers, G. A. P., and Plukker, J. T. M.
- Published
- 2024
- Full Text
- View/download PDF
3. Staging laparoscopy in gastric cancer patients: From a Dutch nationwide Delphi consensus towards a standardized protocol
- Author
-
van Berge Henegouwen, M.I., Gisbertz, S.S., Eshuis, W.J., Daams, F., Borstlap, W.A., Luyer, M.D.P., Simkens, G.A., Nieuwenhuizen, G.A.P., van der Sluis, P.C., Lagarde, S.M., Noordman, B.J., Heisterkamp, J., Matthijsen, R.A., Matthée, E.P.C., Wassenaar, E.B., Pierik, E.G.J.M., Hartgrink, H.H., de Steur, W.O., Hutteman, M., van der Harst, E., Pierie, J.E.N., Emous, M., Kelder, W., Hartemink, K.J., Veenhof, A.A.F.A., Hugen, N., Klarenbeek, B.R., van Esser, S., Bilgen, E.J. Spillenaar, Witteman, B.P.L., van Etten, B., Dijkstra, F.A., Haveman, J.W., van der Bilt, A., van Hillegersberg, R., van den Berg, J.W., Brenkman, H.J.F., Kouwenhoven, E.A., van Det, M.J., Stoot, J.H.M.B., Belgers, E.H.J., Sosef, M.N., van der Sluis, Karen, Guchelaar, Niels A.D., Triemstra, Lianne, Mathijssen, Ron H.J., Ruurda, Jelle P., Wijnhoven, Bas P.L., and van Sandick, Johanna W.
- Published
- 2024
- Full Text
- View/download PDF
4. ASO Author Reflections: A Systematic Review on Predictive Immune and Metabolic Biomarkers to Predict Clinical and Pathological Response in Esophageal Cancer
- Author
-
Wang, H. H., Steffens, E. N., Kats-Ugurlu, G., van Etten, B., Burgerhof, J. G. M., Hospers, G. A. P., and Plukker, J. T. M.
- Published
- 2024
- Full Text
- View/download PDF
5. External validation of a lung cancer-based prediction model for two-year mortality in esophageal cancer patient cohorts
- Author
-
Berbée, M., Muijs, C.T., Voncken, F.E.M., Wee, L., Sosef, M., van Etten, B., van Sandick, J.W., Warmerdam, F.A.R.M., de Haan, J.J., Oldehinkel, E., van Dieren, J.M., Boersma, L., Langendijk, J.A., van der Schaaf, A., Reitsma, J.B., and Schuit, E.
- Published
- 2024
- Full Text
- View/download PDF
6. The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancer—results from the RAPIDO trial
- Author
-
Dijkstra, E.A., Zwart, W.H., Nilsson, P.J., Putter, H., Roodvoets, A.G.H., Meershoek-Klein Kranenbarg, E., Frödin, J.E., Nygren, P., Østergaard, L., Kersten, C., Verbiené, I., Cervantes, A., Hendriks, M.P., Capdevila, J., Edhemovic, I., van de Velde, C.J.H., Marijnen, C.A.M., van Etten, B., Hospers, G.A.P., and Glimelius, B.
- Published
- 2023
- Full Text
- View/download PDF
7. Multidisciplinary decision-making in older patients with cancer, does it differ from younger patients?
- Author
-
Festen, S., Nijmeijer, H., van Leeuwen, B.L., van Etten, B., van Munster, B.C., and de Graeff, P.
- Published
- 2021
- Full Text
- View/download PDF
8. Pelvic Floor Rehabilitation After Rectal Cancer Surgery: A Multicenter Randomized Clinical Trial (FORCE Trial)
- Author
-
van der Heijden, J. A. G., Kalkdijk-Dijkstra, A. J., Pierie, J. P. E. N., van Westreenen, H. L., Broens, P. M. A., Klarenbeek, B. R., de Wilt, JHW, Stommel, MWJ, Bremers, AJA, Rosman, C, de Reuver, PR, Bouwense, SAW, van der Kolk, BM, Garms, LM, Meerten-van den Belt, K, Olde Hartman-Hofste, MRM, Peters, JWM, Olsder, L, Huizing, I, Trzpis, M, Furnee, EJB, Havenga, K, Hemmer, PHJ, van Etten, B, Koop, A, van der Heide, L, Kamphuis, D, Koopal, SA, Hoff, C, Eker, H, Junte, HHM, Schoenaker, IJH, Quaedackers, S, Bos, MJ, Gardien, H, van Sprundel, TC, de Vries, PD, Ashruf, JF, Geurts, L, Nielen, I, Pfeil, J, van Ark, M, Polle, SW, Hansson, B, Polat, F, de Vries, H, ten Berge-Groen, E, Talsma, AK, Bosker, R, Veurink, E, Papa, M, Maaskant-Braat, AJG, van den Broek, FJC, Leclercq, WKG, Slooter, GD, Caers, F, Boeijen, M, van den Broek, R, van Schaik, K, Wasowicz-Kemps, DK, Langenhoff, BS, van den Bogaard, MJ, van der Sluis, J, Arisz, D, Bruinsma, S, Hess, DA, Mulder, EJ, Wiering, B, Kok, S, Woltering, J, Raap-van Sleuwen, B, Schoonderwoerd, L, Hendriks, D, van den Elzen, N, van de Laak, I, Valk, M, van der Meij, W, van Wely, BJ, van Hoogstraten, MJ, van der Sluis, M, Paulusma, I, Mollers, MJW, Looijen, R, van der Mijle, HCJ, Pereboom, ITA, Tijink-Callenbach, PMC, Schasfoort, RA, van der Hagen, SJ, van de Meer, W, Lubberink, M, van Haskera, M, Wit, F, Jeeninga, M, ten Hoeve, R, Slootmans, FCW, Inberg, B, de Nes, L, Toonen, D, Wilmsen, MA, Buyne, O, Ferenschild, F, de Vries, M., Adamse, C, Hettema-Beets, BL, Goudswaard, MK, van der Velde, M, Elving, DW, Arends-Smit, RE, Buiter, JR, van der itte-van Aerle, I, Jansma, K, Kooistra, L, Lohof-Venema, S, Kruijer, MR, Dijkstra, G, van der erf-Elling, MA, Kats-de Boer, V, Rinsema, AM, Haarlemmer-Lutjeboer, M, van der Vegt, A, Berends-Pors, SMH, Ponstein, AJ, Klaassen, G, Nieuwint, AM, Veninga-Jansen, M, Dries-Jansen, V, Arends, FJ, Stellingwerf-Goinga, NE, Overmars, NG, van Asma, H, Beverdam, K, Ploumen, MJAC, Tijhuis, M, Visser Duiven, AH, Former, M, Smans-Kaal, MAL, Vorsterman van Oijen-Linthorst, CMJ, Hovels-Kamp, NN, Vorsteveld, LR, Vermeulen, N, Alkemade-van Veghel, A, Steentjes, LJ, Cornelisse-Theunissen, HGM, Strijbosch, J, Sniekers, S, Oerlemans-van Oijen, JMA, Hoefnagels, HMJ, Sniekers, CJDA, Biemans, S, Bomert-Wendt, Y, van Gaal, HGM, Smulders, AHCW, Adams, W, Kappen, JM, Vermeltfoort-Jansen, AM, Zegger, MGC, Vrielink, C, Slotman, HM, Claessens, NJH, Manders-de Groot, AWM, van Beuzekom-van der Vorst, CTPG, Swinkels-Nijssen, MWC, van Oeveren, P, van Leeuwen-Nellestijn, JPF, Bleijenberg, M, Valenteyn-Hidden, JJF, van Rutten-de Groot, MG, van den van der Heijden, M, Nieuwenhuizen, Boorsma, PG, Broodman, N, Elling, ME, Bokkers-Engelen, E, Hilhorst-Droppers, GH, Mein, HJC, and Gielen, M
- Published
- 2022
- Full Text
- View/download PDF
9. A low incidence of perineal hernia when using a biological mesh after extralevator abdominoperineal excision with or without pelvic exenteration or distal sacral resection in locally advanced rectal cancer patients
- Author
-
Dijkstra, E. A., Kahmann, N. L. E., Hemmer, P. H. J., Havenga, K., and van Etten, B.
- Published
- 2020
- Full Text
- View/download PDF
10. Surgical and medical management of small bowel gastrointestinal stromal tumors: A report of the Dutch GIST registry
- Author
-
Boonstra, P.A., Steeghs, N., Farag, S., van Coevorden, F., Gelderblom, H., Grunhagen, D.J., Desar, I.M.E., van der Graaf, W.T.A., Bonenkamp, J.J., Reyners, A.K.L., and van Etten, B.
- Published
- 2019
- Full Text
- View/download PDF
11. Cognitive decline after major oncological surgery in the elderly
- Author
-
Plas, M., Rotteveel, E., Izaks, G.J., Spikman, J.M., van der Wal-Huisman, H., van Etten, B., Absalom, A.R., Mourits, M.J.E., de Bock, G.H., and van Leeuwen, B.L.
- Published
- 2017
- Full Text
- View/download PDF
12. Corrigendum to “Authors’ reply—Does the RAPIDO trial suggest a benefit of post-operative chemotherapy after preoperative chemoradiation in rectal cancer? No, it does not”: [ESMO Open 8 (2023) 101645]
- Author
-
Zwart, W.H., Dijkstra, E.A., Putter, H., Marijnen, C.A.M., Nilsson, P.J., van de Velde, C.J.H., van Etten, B., Hospers, G.A.P., and Glimelius, B.
- Published
- 2023
- Full Text
- View/download PDF
13. Authors’ reply—Does the RAPIDO trial suggest a benefit of post-operative chemotherapy after preoperative chemoradiation in rectal cancer? No, it does not
- Author
-
Zwart, W.H., Dijkstra, E.A., Putter, H., Marijnen, C.A.M., Nilsson, P.J., van de Velde, C.J.H., van Etten, B., Hospers, G.A.P., and Glimelius, B.
- Published
- 2023
- Full Text
- View/download PDF
14. Evaluation of PET and laparoscopy in STagIng advanced gastric cancer: a multicenter prospective study (PLASTIC-study)
- Author
-
Brenkman, H. J. F., Gertsen, E. C., Vegt, E., van Hillegersberg, R., van Berge Henegouwen, M. I., Gisbertz, S. S., Luyer, M. D. P., Nieuwenhuijzen, G. A. P., van Lanschot, J. J. B., Lagarde, S. M., de Steur, W. O., Hartgrink, H. H., Stoot, J. H. M. B., Hulsewe, K. W. E., Spillenaar Bilgen, E. J., van Det, M. J., Kouwenhoven, E. A., van der Peet, D. L., Daams, F., van Sandick, J. W., van Grieken, N. C. T., Heisterkamp, J., van Etten, B., Haveman, J. W., Pierie, J. P., Jonker, F., Thijssen, A. Y., Belt, E. J. T., van Duijvendijk, P., Wassenaar, E., van Laarhoven, H. W. M., Wessels, F. J., Haj Mohammad, N., van Stel, H. F., Frederix, G. W. J., Siersema, P. D., Ruurda, J. P., and on behalf of the PLASTIC Study Group
- Published
- 2018
- Full Text
- View/download PDF
15. Early mobilization after ilio-inguinal lymph node dissection for melanoma does not increase the wound complication rate
- Author
-
Wevers, K.P., Poos, H.P.A.M., van Ginkel, R.J., van Etten, B., and Hoekstra, H.J.
- Published
- 2013
- Full Text
- View/download PDF
16. Consequence of Restaging After Neoadjuvant Treatment for Locally Advanced Rectal Cancer
- Author
-
Bisschop, C., Tjalma, J. J. J., Hospers, G. A. P., Van Geldere, D., de Groot, J. W. B., Wiegman, E. M., Van’t Veer-ten Kate, M., Havenith, M. G., Vecht, J., Beukema, J. C., Kats-Ugurlu, G., Mahesh, S. V. K., van Etten, B., Havenga, K., Burgerhof, J. G. M., de Groot, D. J. A., and de Vos tot Nederveen Cappel, W. H.
- Published
- 2015
- Full Text
- View/download PDF
17. Quality of life, functional outcome and late toxicity in patients treated within the RAPIDO trial
- Author
-
Dijkstra, E., Hospers, G., van de Velde, C., Fleer, J., Bahadoer, R., Guren, M., Tjalma, J., Putter, H., Kranenbarg, E. Meershoek-Klein, Roodvoets, A., ten Tije, A., Capdevila, J., Hendriks, M., Cervantes, A., Nilsson, P., Glimelius, B., van Etten, B., Marijnen, C., Guided Treatment in Optimal Selected Cancer Patients (GUTS), Lifelong Learning, Education & Assessment Research Network (LEARN), and Health Psychology Research (HPR)
- Published
- 2021
18. Isolated hypoxic hepatic perfusion with melphalan in patients with irresectable ocular melanoma metastases
- Author
-
van Etten, B., de Wilt, J.H.W., Brunstein, F., Eggermont, A.M.M., and Verhoef, C.
- Published
- 2009
- Full Text
- View/download PDF
19. Results of Surgery for Perforated Gastroduodenal Ulcers in a Dutch Population
- Author
-
Hemmer, P. H.J., de Schipper, J. S., van Etten, B., Pierie, J. P.E.N., Bonenkamp, J. J., de Graaf, P. W., and Karsten, T. M.
- Published
- 2012
- Full Text
- View/download PDF
20. Balloon catheter hypoxic pelvic perfusion with mitomycin C and melphalan for locally advanced tumours in the pelvic region: A phase I—II trial
- Author
-
van Ijken, M.G.A., van Etten, B., Guetens, G., de Bruijn, E.A., ten Hagen, T.L.M., Wiggers, Th., and Eggermont, A.M.M.
- Published
- 2005
- Full Text
- View/download PDF
21. Biochemotherapeutic strategies and the (dis) utility of hypoxic perfusion of liver, abdomen and pelvis using balloon catheter techniques
- Author
-
van Ijken, M.G.A., van Etten, B., Brunstein, F., ten Hagen, T.L.M., Guetens, G., de Wilt, J.H.W., de Bruijn, E.A., and Eggermont, A.M.M.
- Published
- 2005
- Full Text
- View/download PDF
22. Balloon catheter hypoxic abdominal perfusion with Mitomycin C and Melphalan for locally advanced pancreatic cancer: a phase I–II trial
- Author
-
van IJken, M.G.A, van Etten, B, Guetens, G, ten Hagen, T.L.M, Jeekel, J, de Bruijn, E.A, Eggermont, A.M.M, and van Eijck, C.H.J
- Published
- 2004
- Full Text
- View/download PDF
23. Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): A multicenter observational study
- Author
-
Borggreve, A. S., Mook, S., Verheij, M., Mul, V. E.M., Bergman, J. J., Bartels-Rutten, A., Ter Beek, L. C., Beets-Tan, R. G.H., Bennink, R. J., Van Berge Henegouwen, M. I., Brosens, L. A.A., Defize, I. L., Van Dieren, J. M., Dijkstra, H., Van Hillegersberg, R., Hulshof, M. C., Van Laarhoven, H. W.M., Lam, M. G.E.H., Van Lier, A. L.H.M.W., Muijs, C. T., Nagengast, W. B., Nederveen, A. J., Noordzij, W., Plukker, J. T.M., Van Rossum, P. S.N., Ruurda, J. P., Van Sandick, J. W., Weusten, B. L.A.M., Voncken, F. E.M., Yakar, D., Meijer, G. J., Aleman, B. M.P., Borra, R. J.H., Van Etten, B., Gisbertz, S. S., Goense, L., Haj Mohammad, N., Hartemink, K. J., Kappert, P., Kats-Ugurlu, G., Kodach, L. L., Korteweg, T., Krishnadath, K. K., Langendijk, J. A., De Leng, W. W.J., Meijer, S. L., Potze, J. H., Stoker, J., Vegt, E., Verkooijen, H. M., Vollenbrock, S. E., Wessels, F., Guided Treatment in Optimal Selected Cancer Patients (GUTS), Damage and Repair in Cancer Development and Cancer Treatment (DARE), Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE), Gastroenterology and Hepatology, AGEM - Re-generation and cancer of the digestive system, Nuclear Medicine, Radiology and Nuclear Medicine, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Surgery, CCA - Imaging and biomarkers, Radiotherapy, Oncology, ACS - Diabetes & metabolism, AMS - Restoration & Development, ANS - Brain Imaging, Pathology, and AGEM - Digestive immunity
- Subjects
Cancer Research ,Esophageal Neoplasms ,PREDICTION ,SURGERY ,medicine.medical_treatment ,Esophageal cancer ,FREE DNA ,Study Protocol ,0302 clinical medicine ,Positron Emission Tomography Computed Tomography ,Pathologic complete response ,PATHOLOGICAL COMPLETE RESPONSE ,FDG-PET ,medicine.diagnostic_test ,Image-guided ,Chemoradiotherapy ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Primary tumor ,Neoadjuvant Therapy ,Neoadjuvant chemoradiotherapy ,medicine.anatomical_structure ,Fine-needle aspiration ,Treatment Outcome ,Oncology ,Positron emission tomography ,Esophagectomy ,030220 oncology & carcinogenesis ,GASTROESOPHAGEAL CANCER ,Adenocarcinoma ,030211 gastroenterology & hepatology ,Radiology ,Rare cancers Radboud Institute for Health Sciences [Radboudumc 9] ,MRI ,medicine.medical_specialty ,DCE-MRI ,PET-CT ,lcsh:RC254-282 ,03 medical and health sciences ,POSITRON-EMISSION-TOMOGRAPHY ,DW-MRI ,Preoperative Care ,medicine ,Genetics ,Humans ,Esophagus ,JUNCTIONAL CANCER ,business.industry ,PERIOPERATIVE CHEMOTHERAPY ,ctDNA ,medicine.disease ,CIRCULATING TUMOR-CELLS ,business ,Follow-Up Studies - Abstract
Contains fulltext : 200332.pdf (Publisher’s version ) (Open Access) BACKGROUND: Nearly one third of patients undergoing neoadjuvant chemoradiotherapy (nCRT) for locally advanced esophageal cancer have a pathologic complete response (pCR) of the primary tumor upon histopathological evaluation of the resection specimen. The primary aim of this study is to develop a model that predicts the probability of pCR to nCRT in esophageal cancer, based on diffusion-weighted magnetic resonance imaging (DW-MRI), dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and (18)F-fluorodeoxyglucose positron emission tomography with computed tomography ((18)F-FDG PET-CT). Accurate response prediction could lead to a patient-tailored approach with omission of surgery in the future in case of predicted pCR or additional neoadjuvant treatment in case of non-pCR. METHODS: The PRIDE study is a prospective, single arm, observational multicenter study designed to develop a multimodal prediction model for histopathological response to nCRT for esophageal cancer. A total of 200 patients with locally advanced esophageal cancer - of which at least 130 patients with adenocarcinoma and at least 61 patients with squamous cell carcinoma - scheduled to receive nCRT followed by esophagectomy will be included. The primary modalities to be incorporated in the prediction model are quantitative parameters derived from MRI and (18)F-FDG PET-CT scans, which will be acquired at fixed intervals before, during and after nCRT. Secondary modalities include blood samples for analysis of the presence of circulating tumor DNA (ctDNA) at 3 time-points (before, during and after nCRT), and an endoscopy with (random) bite-on-bite biopsies of the primary tumor site and other suspected lesions in the esophagus as well as an endoscopic ultrasonography (EUS) with fine needle aspiration of suspected lymph nodes after finishing nCRT. The main study endpoint is the performance of the model for pCR prediction. Secondary endpoints include progression-free and overall survival. DISCUSSION: If the multimodal PRIDE concept provides high predictive performance for pCR, the results of this study will play an important role in accurate identification of esophageal cancer patients with a pCR to nCRT. These patients might benefit from a patient-tailored approach with omission of surgery in the future. Vice versa, patients with non-pCR might benefit from additional neoadjuvant treatment, or ineffective therapy could be stopped. TRIAL REGISTRATION: The article reports on a health care intervention on human participants and was prospectively registered on March 22, 2018 under ClinicalTrials.gov Identifier: NCT03474341 .
- Published
- 2018
24. Ferumoxide-enhanced magnetic resonance imaging techniques in pre-operative assessment for colorectal liver metastases
- Author
-
van Etten, B., van der Sijp, J.R.M., Kruyt, R.H., Oudkerk, M., van der Holt, B., and Wiggers, Th.
- Published
- 2002
- Full Text
- View/download PDF
25. Exploiting metabolic acidosis in solid cancers using a tumor-agnostic pH-activatable nanoprobe for fluorescence-guided surgery.
- Author
-
Voskuil, F. J., Steinkamp, P. J., Zhao, T., van der Vegt, B., Koller, M., Doff, J. J., Jayalakshmi, Y., Hartung, J. P., Gao, J., Sumer, B. D., Witjes, M. J. H., van Dam, G. M., the SHINE study group, Albaroodi, Y., Been, L. B., Dijkstra, F., van Etten, B., Feng, Q., van Ginkel, R. J., and Hall, K.
- Subjects
ACIDOSIS ,CLINICAL trial registries ,CANCER ,INDOCYANINE green ,TUMOR microenvironment - Abstract
Cancer cell metabolism leads to a uniquely acidic microenvironment in solid tumors, but exploiting the labile extracellular pH differences between cancer and normal tissues for clinical use has been challenging. Here we describe the clinical translation of ONM-100, a nanoparticle-based fluorescent imaging agent. This is comprised of an ultra-pH sensitive amphiphilic polymer, conjugated with indocyanine green, which rapidly and irreversibly dissociates to fluoresce in the acidic extracellular tumor microenvironment due to the mechanism of nanoscale macromolecular cooperativity. Primary outcomes were safety, pharmacokinetics and imaging feasilibity of ONM-100. Secondary outcomes were to determine a range of safe doses of ONM-100 for intra-operative imaging using commonly used fluorescence camera systems. In this study (Netherlands National Trial Register #7085), we report that ONM-100 was well tolerated, and four solid tumor types could be visualized both in- and ex vivo in thirty subjects. ONM-100 enables detection of tumor-positive resection margins in 9/9 subjects and four additional otherwise missed occult lesions. Consequently, this pH-activatable optical imaging agent may be clinically beneficial in differentiating previously unexploitable narrow physiologic differences. It is well known that the pH of tumor tissue is lower than that of the corresponding normal adjacent tissue. Here, the authors report a clinical trial of a pH activatable nanoparticle for imaging tumours. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
26. Nationwide Outcome of Gastrectomy with En-Bloc Partial Pancreatectomy for Gastric Cancer.
- Author
-
van der Werf, L. R., Eshuis, W. J., Draaisma, W. A., van Etten, B., Gisbertz, S. S., van der Harst, E., Liem, M. S. L., Lemmens, V. E. P. P., Wijnhoven, B. P. L., Besselink, M. G., van Berge Henegouwen, M. I., on behalf of the Dutch Upper Gastrointestinal Cancer Audit (DUCA) group., van Hillegersberg, R., van Eijden, Y., van Esser, S., Hartgrink, H. H., de Jong, G., Karsten, T. M., Kouwenhoven, E. A., and Lagarde, S. M.
- Subjects
PANCREATECTOMY ,STOMACH cancer ,GASTRECTOMY ,SURGICAL complications ,PANCREATIC tumors ,LOGISTIC regression analysis - Abstract
Background: Radical gastrectomy is the cornerstone of the treatment of gastric cancer. For tumors invading the pancreas, en-bloc partial pancreatectomy may be needed for a radical resection. The aim of this study was to evaluate the outcome of gastrectomies with partial pancreatectomy for gastric cancer.Methods: Patients who underwent gastrectomy with or without partial pancreatectomy for gastric or gastro-oesophageal junction cancer between 2011 and 2015 were selected from the Dutch Upper GI Cancer Audit (DUCA). Outcomes were resection margin (pR0) and Clavien-Dindo grade ≥ III postoperative complications and survival. The association between partial pancreatectomy and postoperative complications was analyzed with multivariable logistic regression. Overall survival of patients with partial pancreatectomy was estimated using the Kaplan-Meier method.Results: Of 1966 patients that underwent gastrectomy, 55 patients (2.8%) underwent en-bloc partial pancreatectomy. A pR0 resection was achieved in 45 of 55 patients (82% versus 85% in the group without additional resection, P = 0.82). Clavien-Dindo grade ≥ III complications occurred in 21 of 55 patients (38% versus 17%, P < 0.001). Median overall survival [95% confidence interval] was 15 [6.8-23.2] months. For patients with and without perioperative systemic therapy, median survival was 20 [12.3-27.7] and 10 [5.7-14.3] months, and for patients with pR0 and pR1 resection, it was 20 [11.8-28.3] and 5 [2.4-7.6] months, respectively.Conclusions: Gastrectomy with partial pancreatectomy is not only associated with a pR0 resection rate of 82% but also with increased postoperative morbidity. It should only be performed if a pR0 resection is feasible. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
27. SIOG2023-4-P-262 - Improving communication in treatment decision making between primary and secondary care: a pilot.
- Author
-
Hanewinkel, V.C., Stegmann, M., Festen, S., Van der Wal - Huisman, H., Van Etten, B., Van den Boom, A.L., and Brandenbarg, D.
- Published
- 2023
- Full Text
- View/download PDF
28. Repeat isolated limb perfusions (ILP) with tumor necrosis factor-α (TNF) and melphalan are highly effective in melanoma patients with multiple in-transit metastases who have failed prior ILPs
- Author
-
Van Etten, B., Grunhagen, D., Brunstein, F., De Wilt, J., Van Geel, A., and Eggermont, A.
- Published
- 2004
- Full Text
- View/download PDF
29. Randomized clinical trial of biodegradeable intraluminal sheath to prevent anastomotic leak after stapled colorectal anastomosis.
- Author
-
Bakker, I. S., Morks, A. N., ten Cate Hoedemaker, H. O., Burgerhof, J. G. M., Leuvenink, H. G., van Praagh, J. B., Ploeg, R. J., Havenga, K., van Etten, B., Lange, J. F. M., Hemmer, P. H. J., Sonneveld, D. J. A., Tanis, P. J., Wegdam, J. A., Jonk, A., Lutke Holzik, M. F., Bosker, R. J. I., Lamme, B., Spillenaar Bilgen, E. J., and Bremers, A. J.
- Subjects
INTRAVASCULAR ultrasonography ,SURGICAL anastomosis ,PROCTOLOGY ,SURGICAL wound dehiscence ,ELECTIVE surgery - Abstract
Background Anastomotic leakage is a potential major complication after colorectal surgery. The C-seal was developed to help reduce the clinical leakage rate. It is an intraluminal sheath that is stapled proximal to a colorectal anastomosis, covering it intraluminally and thus preventing intestinal leakage in case of anastomotic dehiscence. The C-seal trial was initiated to evaluate the efficacy of the C-seal in reducing anastomotic leakage in stapled colorectal anastomoses. Methods This RCT was performed in 41 hospitals in the Netherlands, Germany, France, Hungary and Spain. Patients undergoing elective surgery with a stapled colorectal anastomosis less than 15 cm from the anal verge were eligible. Included patients were randomized to the C-seal and control groups, stratified for centre, anastomotic height and intention to create a defunctioning stoma. Primary outcome was anastomotic leakage requiring invasive treatment. Results Between December 2011 and December 2013, 402 patients were included in the trial, 202 in the C-seal group and 200 in the control group. Anastomotic leakage was diagnosed in 31 patients (7·7 per cent), with a 10·4 per cent leak rate in the C-seal group and 5·0 per cent in the control group ( P = 0·060). Male sex showed a trend towards a higher leak rate ( P = 0·055). Construction of a defunctioning stoma led to a lower leakage rate, although this was not significant ( P = 0·095). Conclusion C-seal application in stapled colorectal anastomoses does not reduce anastomotic leakage. Registration number: NTR3080 (). [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
30. Rectal and colon cancer: Not just a different anatomic site.
- Author
-
Tamas, K., Walenkamp, A.M.E., de Vries, E.G.E., van Vugt, M.A.T.M., Beets-Tan, R.G., van Etten, B., de Groot, D.J.A., and Hospers, G.A.P.
- Abstract
Due to differences in anatomy, primary rectal and colon cancer require different staging procedures, different neo-adjuvant treatment and different surgical approaches. For example, neoadjuvant radiotherapy or chemoradiotherapy is administered solely for rectal cancer. Neoadjuvant therapy and total mesorectal excision for rectal cancer might be responsible in part for the differing effect of adjuvant systemic treatment on overall survival, which is more evident in colon cancer than in rectal cancer. Apart from anatomic divergences, rectal and colon cancer also differ in their embryological origin and metastatic patterns. Moreover, they harbor a different composition of drug targets, such as v-raf murine sarcoma viral oncogene homolog B (BRAF), which is preferentially mutated in proximal colon cancers, and the epidermal growth factor receptor (EGFR), which is prevalently amplified or overexpressed in distal colorectal cancers. Despite their differences in metastatic pattern, composition of drug targets and earlier local treatment, metastatic rectal and colon cancer are, however, commonly regarded as one entity and are treated alike. In this review, we focused on rectal cancer and its biological and clinical differences and similarities relative to colon cancer. These aspects are crucial because they influence the current staging and treatment of these cancers, and might influence the design of future trials with targeted drugs. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
31. Impaired neutralising antibody formation and high transduction efficacy after isolated hepatic perfusion with adenoviral vectors.
- Author
-
van Etten, B, Eggermont, A M M, Ambagtsheer, G, van Tiel, S T, and ten Hagen, T L M
- Subjects
- *
ADENOVIRUS diseases , *DNA viruses , *ADENOVIRUSES , *IMMUNE response , *IMMUNOGLOBULINS , *IMMUNOLOGY , *VIRUSES , *GENETICS , *CANCER chemotherapy , *LIVER , *RATS , *ANTIBODY formation , *NEUTRALIZATION tests , *GENES , *GENETIC techniques , *VIRAL antibodies , *ANIMALS - Abstract
Local adenoviral gene transfer can be performed by means of isolated hepatic perfusion (IHP). This methodology is a very effective and safe way to deliver adenoviral vectors. We studied the immune response after IHP. A decreased neutralising antibody formation was observed, offering possibilities for further research in the field of gene therapy in isolated perfusion settings. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
32. Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-alpha-based isolated hepatic perfusion.
- Author
-
van Etten, B, de Vries, M R, van IJken, M G A, Lans, T E, Guetens, G, Ambagtsheer, G, van Tiel, S T, de Boeck, G, de Bruijn, E A, Eggermont, A M M, and ten Hagen, T L M
- Subjects
- *
LIVER tumors , *TUMOR necrosis factors , *METASTASIS - Abstract
Isolated hepatic perfusion (IHP) with melphalan with or without tumour necrosis factor alpha (TNF-alpha) is currently performed in clinical trials in patients with hepatic metastases. Previous studies led to the hypothesis that the use of TNF-alpha in isolated limb perfusion causes specific destruction of tumour endothelial cells and thereby induces an increased permeability of tumour vasculature. However, whether TNF-alpha contributes to the therapeutic efficacy in IHP still remains unclear. In an in vivo rat liver metastases model we studied three different tumours: colon carcinoma CC531, ROS-1 osteosarcoma and BN-175 soft-tissue sarcoma which exhibit different degrees of vascularisation. IHP was performed with melphalan with or without the addition of TNF-alpha. IHP with melphalan alone resulted, in all tumour types, in a decreased growth rate. However in the BN-175 tumour addition of TNF-alpha resulted in a strong synergistic effect. In the majority of the BN-175 tumour-bearing rats, a complete response was achieved. In vitro cytoxicity studies showed no sensitivity (CC531 and BN-175) or only minor sensitivity (ROS-1) to TNF-alpha, ruling out a direct interaction of TNF-alpha with tumour cells. The response rate in BN-175 tumour-bearing rats when TNF-alpha was coadministrated with melphalan was strongly correlated with drug accumulation in tumour tissue, as only in these rats a five-fold increased melphalan concentration was observed. Secondly, immunohistochemical analysis of microvascular density (MVD) of the tumour showed a significantly higher MVD for BN-175 tumour compared to CC531 and ROS-1. These results indicate a direct relation between vascularity of the tumour and TNF-alpha mediated effects. Assessment of the tumour vasculature of liver metastases would be a way of establishing an indication for the utility of TNF-alpha in this setting. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
33. Prerequisites for effective adenovirus mediated gene therapy of colorectal liver metastases in the rat using an intracellular neutralizing antibody fragment to p21-Ras.
- Author
-
van Etten, B., ten Hagen, T.L.M., de Vries, M.R., Ambagtsheer, G., Huet, T., and Eggermont, A.M.M.
- Subjects
- *
LIVER metastasis , *COLON cancer , *ADENOVIRUSES , *GENE therapy - Abstract
Ras mutations are present in 40-50% of colorectal cancers. Inactivating this oncogene may therefore reduce proliferation capacity. In order to target ras we studied the transduction efficacy and anti tumour activity of an adenoviral vector expressing an intracellular, neutralizing single chain antibody to p21-ras (Y28). In in vitro studies transfection levels of the K-ras mutated rat colon carcinoma cell line CC531 were studied using the LacZ marker gene. In our in vivo liver metastases model different routes of administration were evaluated to determine which regimen resulted in the best transfection levels and tumour responses: intravenous injection, intratumoural injection, isolated liver perfusion, or hepatic artery infusion. CC531 cells are readily transfected in vitro, resulting in significant inhibition of tumour cell proliferation by the Y28 construct. Intravenous injection did not result in any measurable transfection. Intratumoural injection resulted only in the transfection of tumour cells along the needle track. IHP as well as single HAI achieved low transfection levels of tumour tissue. Expression of Y28 was demonstrated in tumours after IT injection, HAI and IHP. Whereas, repeated HAI's clearly achieved expression in and around tumour associated vessels. Only five times repeated HAI's with Y28 resulted in a tumour response: in all animals tumour growth was inhibited, and in three rats out of eight a complete regression of the liver tumours was observed. [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
34. Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions.
- Author
-
de Wilt, J H W, Manusama, E R, van Etten, B, van Tiel, S T, Jorna, A S, Seynhaeve, A L B, and ten Hagen, T L M
- Subjects
NITRIC oxide ,NEOVASCULARIZATION inhibitors - Abstract
Nitric oxide (NO) is an important molecule in regulating tumour blood flow and stimulating tumour angiogenesis. Inhibition of NO synthase by L-NAME might induce an anti-tumour effect by limiting nutrients and oxygen to reach tumour tissue or affecting vascular growth. The anti-tumour effect of L-NAME after systemic administration was studied in a renal subcapsular CC531 adenocarcinoma model in rats. Moreover, regional administration of L-NAME, in combination with TNF and melphalan, was studied in an isolated limb perfusion (ILP) model using BN175 soft-tissue sarcomas. Systemic treatment with L-NAME inhibited growth of adenocarcinoma significantly but was accompanied by impaired renal function. In ILP, reduced tumour growth was observed when L-NAME was used alone. In combination with TNF or melphalan, L-NAME increased response rates significantly compared to perfusions without L-NAME (0-64% and 0-63% respectively). An additional anti-tumour effect was demonstrated when L-NAME was added to the synergistic combination of melphalan and TNF (responses increased from 70 to 100%). Inhibition of NO synthase reduces tumour growth both after systemic and regional (ILP) treatment. A synergistic anti-tumour effect of L-NAME is observed in combination with melphalan and/or TNF using ILP. These results indicate a possible role of L-NAME for the treatment of solid tumours in a systemic or regional setting. [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
35. Torsion of the gallbladder.
- Author
-
Boonstra EA, van Etten B, Prins TR, Sieders E, van Leeuwen BL, Boonstra, Elizabeth A, van Etten, Boudewijn, Prins, Ted R, Sieders, Egbert, and van Leeuwen, Barbara L
- Abstract
Introduction: A 77-year-old woman was seen with progressive abdominal pain.Cases: A CT scan was made and showed a large gallbladder extending into the right lower abdomen. Ultrasound was performed but demonstrated no gallstones. Laparoscopy showed a tordated, necrotic gallbladder that was attached to the liver only by the cystic artery and cystic duct. Cholecystectomy was performed.Conclusions: Torsion of the gallbladder is a rare but clinically important condition in which the diagnosis seldom is made preoperatively. In radiological and clinical signs of cholecystitis without gallstones, this condition should be considered. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
36. Predictive value of the high-risk histopathological criteria in appendiceal neuroendocrine tumours and their correlation with lymph node status in additional right hemicolectomy
- Author
-
Loveikyte, R., van Etten, B., Hemmer, P., Walenkamp, A., Kats-Ugurlu, G., and Guided Treatment in Optimal Selected Cancer Patients (GUTS)
37. Authors' reply—A sensitivity analysis of the RAPIDO clinical trial.
- Author
-
Dijkstra, E.A., Zwart, W.H., Putter, H., Marijnen, C.A.M., Nilsson, P.J., van de Velde, C.J.H., van Etten, B., Hospers, G.A.P., and Glimelius, B.
- Subjects
- *
SENSITIVITY analysis , *CLINICAL trials , *AUTHORS - Published
- 2023
- Full Text
- View/download PDF
38. Spleen Dose Influences Overall Survival In The Neo-Adjuvant Treatment Of Esophageal Cancer.
- Author
-
Muijs, C., Oldehinkel, E., Dieters, M., Mul, V., Nieznik, A., Van den Bergh, A.C.M., de Haan, J.J., Van Etten, B., van der Schaaf, A., and Langendijk, J.A.
- Subjects
- *
ESOPHAGEAL cancer , *SPLEEN , *CANCER treatment - Published
- 2020
- Full Text
- View/download PDF
39. Improving Cancer Treatment Communication between Secondary and Primary Care: A New Format for Written Communication.
- Author
-
Hanewinkel VC, Stegmann ME, Festen S, van der Wal-Huisman H, van Etten B, van den Boom AL, and Brandenbarg D
- Abstract
In decision making for cancer treatment, information is crucial for patients and health care professionals. Although conversations about treatment decisions take place in hospitals, many patients also appreciate the insights of their general practitioner (GP). GPs indicated that, in order to have meaningful conversations about treatment decisions with their patients, they need additional information about treatment options and considerations, such as expected benefits and side effects. In this practice innovation, we developed and implemented a new written communication format from medical specialists to GPs, aimed at providing accurate treatment information to facilitate GPs in supporting patients with cancer in decision-making. The new format added 3 specific headings to standard letters in the electronic patient files (EPFs): (1) treatment options, (2) treatment considerations, and (3) treatment intent. This innovation was implemented in a large university hospital in the Netherlands between 2020 and 2021. We performed a process evaluation of the implementation using the RE-AIM model, based on assessment of written communication obtained from patients' EPFs, and telephonic interviews with specialists and GPs. In the Netherlands, all inhabitants are registered with a GP, who acts as a gatekeeper to specialist care, and has a comprehensive overview of a patient's history, based on digital communication with hospitals after referral for specialist care. EPFs are used to generate digital letters to communicate between medical specialists in a hospital and GPs outside the hospital. Incorporating new headings in the communication format in the EPF successfully encouraged medical specialists to share such information when used appropriately. Treatment options, considerations, and treatment intent were stated more often in the new format compared with the old format. GPs appreciated the new format, highlighting the value of including treatment considerations, which enhanced their comprehension of the medical specialist's thought processes. Recognition of the problem and motivation for improvement facilitated the implementation. Specialists stated the format to be time-efficient compared with the old format; however, technical improvements could make it easier to use. Automaticity to use of the old format, inadequate information, and technical issues were a barrier for implementation. In summary, a straightforward innovation can improve communication between medical specialists and GPs and promote the role of the GPs in decision making for cancer treatment., Competing Interests: Disclosures The authors declare no conflicts of interest., (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
40. Ultrasound-Guided Quantitative Fluorescence Molecular Endoscopy for Monitoring Response in Patients with Esophageal Cancer Following Neoadjuvant Chemoradiotherapy.
- Author
-
Schmidt I, Zhao X, van der Waaij AM, Meersma GJ, Dijkstra FA, Haveman JW, van Etten B, Robinson DJ, Kats-Ugurlu G, and Nagengast WB
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Chemoradiotherapy methods, Bevacizumab administration & dosage, Treatment Outcome, Fluorescence, Esophageal Neoplasms therapy, Esophageal Neoplasms pathology, Esophageal Neoplasms diagnostic imaging, Esophageal Neoplasms diagnosis, Neoadjuvant Therapy methods
- Abstract
Purpose: The ability to identify residual tumor tissues in patients with locally advanced esophageal cancer following neoadjuvant chemoradiotherapy (nCRT) is essential for monitoring the treatment response. Using the fluorescent tracer bevacizumab-800CW, we evaluated whether ultrasound-guided quantitative fluorescent molecular endoscopy (US-qFME), which combines quantitative fluorescence molecular endoscopy (qFME) with ultrasound-guided needle biopsy/single-fiber fluorescence (USNB/SFF), can be used to identify residual tumor tissues in patients following nCRT., Experimental Design: Twenty patients received an additional endoscopy procedure the day before surgery. qFME was performed at the primary tumor site (PTS) and in healthy tissue to first establish the optimal tracer dose. USNB/SFF was then used to measure intrinsic fluorescence in the deeper PTS layers and lymph nodes (LN) suspected for metastasis. Finally, the intrinsic fluorescence and the tissue optical properties-specifically, the absorption and reduced scattering coefficients-were combined into a new parameter called omega., Results: First, a 25-mg bevacizumab-800CW dose allowed for clear differentiation between the PTS and healthy tissue, with a target-to-background ratio (TBR) of 2.98 (IQR, 1.86-3.03). Moreover, we found a clear difference between the deeper esophageal PTS layers and suspected LN compared to healthy tissues, with TBR values of 2.18 and 2.17, respectively. Finally, our new parameter, omega, further improved the ability to differentiate between the PTS and healthy tissue., Conclusions: Combining bevacizumab-800CW with US-qFME may serve as a viable strategy for monitoring the response to nCRT in esophageal cancer and may help stratify patients regarding active surveillance versus surgery., (©2024 American Association for Cancer Research.)
- Published
- 2024
- Full Text
- View/download PDF
41. Surgical Techniques and Related Perioperative Outcomes After Robot-assisted Minimally Invasive Gastrectomy (RAMIG): Results From the Prospective Multicenter International Ugira Gastric Registry.
- Author
-
de Jongh C, Cianchi F, Kinoshita T, Kingma F, Piccoli M, Dubecz A, Kouwenhoven E, van Det M, Mala T, Coratti A, Ubiali P, Turner P, Kish P, Borghi F, Immanuel A, Nilsson M, Rouvelas I, Hӧlzen JP, Rouanet P, Saint-Marc O, Dussart D, Patriti A, Bazzocchi F, van Etten B, Haveman JW, DePrizio M, Sabino F, Viola M, Berlth F, Grimminger PP, Roviello F, van Hillegersberg R, and Ruurda J
- Subjects
- Humans, Male, Prospective Studies, Female, Middle Aged, Aged, Postoperative Complications epidemiology, Treatment Outcome, Lymph Node Excision methods, Minimally Invasive Surgical Procedures methods, Gastrectomy methods, Robotic Surgical Procedures, Stomach Neoplasms surgery, Registries
- Abstract
Objective: To gain insight into the global practice of robot-assisted minimally invasive gastrectomy (RAMIG) and evaluate perioperative outcomes using an international registry., Background: The techniques and perioperative outcomes of RAMIG for gastric cancer vary substantially in the literature., Methods: Prospectively registered RAMIG cases for gastric cancer (≥10 per center) were extracted from 25 centers in Europe, Asia, and South-America. Techniques for resection, reconstruction, anastomosis, and lymphadenectomy were analyzed and related to perioperative surgical and oncological outcomes. Complications were uniformly defined by the Gastrectomy Complications Consensus Group., Results: Between 2020 and 2023, 759 patients underwent total (n=272), distal (n=465), or proximal (n=22) gastrectomy (RAMIG). After total gastrectomy with Roux-en-Y-reconstruction, anastomotic leakage rates were 8% with hand-sewn (n=9/111) and 6% with linear stapled anastomoses (n=6/100). After distal gastrectomy with Roux-en-Y (67%) or Billroth-II-reconstruction (31%), anastomotic leakage rates were 3% with linear stapled (n=11/433) and 0% with hand-sewn anastomoses (n=0/26). Extent of lymphadenectomy consisted of D1+ (28%), D2 (59%), or D2+ (12%). Median nodal harvest yielded 31 nodes (interquartile range: 21-47) after total and 34 nodes (interquartile range: 24-47) after distal gastrectomy. R0 resection rates were 93% after total and 96% distal gastrectomy. The hospital stay was 9 days after total and distal gastrectomy, and was median 3 days shorter without perianastomotic drains versus routine drain placement. Postoperative 30-day mortality was 1%., Conclusions: This large multicenter study provided a worldwide overview of current RAMIG techniques and their respective perioperative outcomes. These outcomes demonstrated high surgical quality, set a quality standard for RAMIG, and can be considered an international reference for surgical standardization., Competing Interests: J.R.: Consulting or Advisory Role: Intuitive Surgical. R.v.H.: Consulting or Advisory Role: Intuitive Surgical, Medtronic. T.K.: honorarium for lectures for Intuitive Surgical, Medtronic, Johnson & Johnson, and Olympus. E.K.: Consulting or Advisory Role: Intuitive Surgical. M.v.D.: Consulting or Advisory Role: Intuitive Surgical. J.P.H.: Consulting or Advisory Role: Intuitive Surgical. P.R.: Consulting or Advisory Role: Intuitive Surgical. O.S.-M.: Consulting or Advisory Role: Intuitive Surgical. The remaining authors report no conflicts of interest., (Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2024
- Full Text
- View/download PDF
42. Oncological outcomes after a pathological complete response following total neoadjuvant therapy or chemoradiotherapy for high-risk locally advanced rectal cancer in the RAPIDO trial.
- Author
-
Zwart WH, Temmink SJD, Hospers GAP, Marijnen CAM, Putter H, Nagtegaal ID, Blomqvist L, Kranenbarg EM, Roodvoets AGH, Martling A, van de Velde CJH, Glimelius B, Peeters KCMJ, van Etten B, and Nilsson PJ
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Treatment Outcome, Neoplasm Recurrence, Local pathology, Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Rectal Neoplasms pathology, Rectal Neoplasms therapy, Rectal Neoplasms mortality, Neoadjuvant Therapy mortality, Neoadjuvant Therapy methods, Chemoradiotherapy methods
- Abstract
Background: A pathological complete response (pCR) following chemoradiation (CRT) or short-course radiotherapy (scRT) leads to a favourable prognosis in patients with rectal cancer. Total neo-adjuvant therapy (TNT) doubles the pCR rate, but it is unknown whether oncological outcomes remain favourable and whether the same characteristics are associated with pCR as after CRT., Methods: Comparison between patients with pCR in the RAPIDO trial in the experimental [EXP] (scRT, chemotherapy, surgery, as TNT) and standard-of-care treatment [STD] (CRT, surgery, postoperative chemotherapy depending on hospital policy) groups. Primary and secondary outcomes were time-to-recurrence (TTR), overall survival (OS) and association between patient, tumour, and treatment characteristics and pCR., Results: Among patients with a resection within six months after preoperative treatment, 120/423 (28%) [EXP] and 57/398 (14%) [STD] achieved a pCR. Following pCR, 5-year cumulative TTR and OS rates in the EXP and STD arms were 8% vs. 7% (hazard ratio 1.04, 95%CI 0.32-3.38) and 94% vs. 93% (hazard ratio 1.41, 95%CI 0.51-3.92), respectively. Besides the EXP treatment (odds ratio 2.70, 95%CI 1.83-3.97), pre-treatment carcinoembryonic antigen (CEA) <5, pre-treatment tumour size <40 mm and cT2 were associated with pCR. Distance from the anal verge was the only characteristic with a statistically significant difference in association with pCR between the EXP and STD treatment (P
interaction =0.042). pCR rates did not increase with prolonged treatment time., Conclusions: The doubled pCR rate of TNT compared to CRT results in similar oncological outcomes. Characteristics associated with pCR are the EXP treatment, normal CEA, and small tumour size., Competing Interests: Declaration of Competing Interest PJN reports honoraria from Ethicon, Johnson & Johnson, and Amgen. GAPH reports consulting fees from Roche, MSD, Amgen and Novartis; consulting fees and research support to their institution from Bristol Myers Squibb; and research support to their institution from Seerave Foundation. SJDT was fully funded, and AGHR and CJHvdV were partially funded by the EU’s Horizon Skłodowska Curie grant award (H2020MSCAITN2019, grant agreement number 857894; project acronym: CAST). BG reports research support from the Swedish Cancer Society. All other authors have declared no conflicts of interest. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The first authors had full access to all data and had final responsibility for the decision to submit for publication. All other authors report no conflicts of interest., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
43. Impact of 18F FDG-PET/CT and Laparoscopy in Staging of Locally Advanced Gastric Cancer: A Cost Analysis in the Prospective Multicenter PLASTIC-Study.
- Author
-
de Jongh C, van der Meulen MP, Gertsen EC, Brenkman HJF, van Sandick JW, van Berge Henegouwen MI, Gisbertz SS, Luyer MDP, Nieuwenhuijzen GAP, van Lanschot JJB, Lagarde SM, Wijnhoven BPL, de Steur WO, Hartgrink HH, Stoot JHMB, Hulsewe KWE, Spillenaar Bilgen EJ, van Det MJ, Kouwenhoven EA, Daams F, van der Peet DL, van Grieken NCT, Heisterkamp J, van Etten B, van den Berg JW, Pierie JP, Eker HH, Thijssen AY, Belt EJT, van Duijvendijk P, Wassenaar E, Wevers KP, Hol L, Wessels FJ, Haj Mohammad N, Frederix GWJ, van Hillegersberg R, Siersema PD, Vegt E, and Ruurda JP
- Subjects
- Humans, Prospective Studies, Cost-Benefit Analysis, Follow-Up Studies, Prognosis, Costs and Cost Analysis, Male, Female, Stomach Neoplasms pathology, Stomach Neoplasms surgery, Stomach Neoplasms diagnostic imaging, Stomach Neoplasms economics, Laparoscopy economics, Laparoscopy methods, Positron Emission Tomography Computed Tomography economics, Positron Emission Tomography Computed Tomography methods, Neoplasm Staging, Gastrectomy economics, Fluorodeoxyglucose F18 economics, Radiopharmaceuticals economics
- Abstract
Background: Unnecessary D2-gastrectomy and associated costs can be prevented after detecting non-curable gastric cancer, but impact of staging on treatment costs is unclear. This study determined the cost impact of
18 F-fluorodeoxyglucose positron emission tomography/computed tomography (18F FDG-PET/CT) and staging laparoscopy (SL) in gastric cancer staging., Materials and Methods: In this cost analysis, four staging strategies were modeled in a decision tree: (1)18F FDG-PET/CT first, then SL, (2) SL only, (3)18F FDG-PET/CT only, and (4) neither SL nor18F FDG-PET/CT. Costs were assessed on the basis of the prospective PLASTIC-study, which evaluated adding18F FDG-PET/CT and SL to staging advanced gastric cancer (cT3-4 and/or cN+) in 18 Dutch hospitals. The Dutch Healthcare Authority provided18F FDG-PET/CT unit costs. SL unit costs were calculated bottom-up. Gastrectomy-associated costs were collected with hospital claim data until 30 days postoperatively. Uncertainty was assessed in a probabilistic sensitivity analysis (1000 iterations)., Results:18F FDG-PET/CT costs were €1104 including biopsy/cytology. Bottom-up calculations totaled €1537 per SL. D2-gastrectomy costs were €19,308. Total costs per patient were €18,137 for strategy 1, €17,079 for strategy 2, and €19,805 for strategy 3. If all patients undergo gastrectomy, total costs were €18,959 per patient (strategy 4). Performing SL only reduced costs by €1880 per patient. Adding18F FDG-PET/CT to SL increased costs by €1058 per patient; IQR €870-1253 in the sensitivity analysis., Conclusions: For advanced gastric cancer, performing SL resulted in substantial cost savings by reducing unnecessary gastrectomies. In contrast, routine18F FDG-PET/CT increased costs without substantially reducing unnecessary gastrectomies, and is not recommended due to limited impact with major costs., Trial Registration: NCT03208621. This trial was registered prospectively on 30-06-2017., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
44. Referral patterns of GIST patients: data from a nationwide study.
- Author
-
Roets E, Ijzerman NS, Ho VKY, Desar IME, Reyners AKL, Gelderblom H, Grünhagen DJ, Van Etten B, Van Houdt WJ, Van der Graaf WTA, and Steeghs N
- Subjects
- Humans, Retrospective Studies, Referral and Consultation, Netherlands epidemiology, Gastrointestinal Stromal Tumors therapy, Gastrointestinal Stromal Tumors drug therapy, Antineoplastic Agents therapeutic use, Gastrointestinal Neoplasms epidemiology, Gastrointestinal Neoplasms therapy
- Abstract
Background: This study compares the characteristics, referral and treatment patterns and overall survival (OS) of gastrointestinal stromal tumor (GIST) patients treated in reference and non-reference centers in the Netherlands., Patients and Methods: This retrospective cohort study on patients diagnosed between 2016 and 2019, utilises data from the Netherlands Cancer Registry and the Dutch Nationwide Pathology Database. Patients were categorized into two groups: patients diagnosed in or referred to reference centers and patients diagnosed in non-reference centers without referral., Results: This study included 1,550 GIST patients with a median age of 67.0 in reference and 68.0 years in non-reference centers. Eighty-seven per cent of patients were diagnosed in non-reference centers, of which 36.5% (493/1,352) were referred to a reference center. Referral rates were higher for high-risk (62.2% [74/119]) and metastatic patients (67.2% [90/134]). Mutation analysis was performed in 96.9% and 87.6% of these cases in reference and in non-reference centers (p < 0.01), respectively. Systemic therapy was given in reference centers versus non-reference in 89.5% versus 82.0% (p < 0.01) of high-risk and in 94.1% versus 65.9% (p < 0.01) of metastatic patients, respectively. The proportion of positive resection margins and tumor rupture did not differ between reference and non-reference centers. Median OS was not reached., Conclusion: A substantial amount of metastatic GIST patients in non-reference centers did not receive systemic treatment. This might be due to valid reasons. However, optimisation of the referral strategy of GIST patients in the Netherlands could benefit patients. Further research is needed to explore reasons for not starting systemic treatment in metastatic GIST patients.
- Published
- 2024
- Full Text
- View/download PDF
45. Comment on the RAPIDO Trial Point-Counterpoint Debate.
- Author
-
Nilsson PJ, van Etten B, Hospers GAP, Marijnen CAM, Meershoek-Klein Kranenberg E, Roodvoets AGH, van de Velde CJH, and Glimelius B
- Published
- 2024
- Full Text
- View/download PDF
46. N3 Disease in Esophageal Cancer: Results from a Nationwide Registry.
- Author
-
van der Zijden CJ, Olthof PB, van der Sluis PC, Wijnhoven BPL, Erodotou M, Hartgrink HH, van Etten B, van Esser S, Lagarde SM, and Dekker JWT
- Subjects
- Humans, Male, Female, Netherlands, Middle Aged, Aged, Survival Rate, Chemoradiotherapy, Adult, Esophageal Neoplasms therapy, Esophageal Neoplasms pathology, Esophageal Neoplasms mortality, Registries, Esophagectomy, Neoplasm Staging, Neoadjuvant Therapy, Lymphatic Metastasis
- Abstract
Background: Patients with extensive lymph node metastases have a poor prognosis. Clinical staging of lymph node metastases poses significant challenges given the limited sensitivity and specificity of imaging techniques. The aim of this study was to investigate the overall survival (OS) of patients with N3 disease in a real-world Dutch population and the added value of surgery in these patients., Methods: Patients with cN3M0 esophageal or gastroesophageal cancer were identified from the Netherlands Cancer Registry (2012-2019). Treatment consisted of neoadjuvant chemo(radio)therapy followed by resection or chemo(radio)therapy, radiotherapy, or esophagectomy alone. OS was calculated using the Kaplan-Meier method., Results: Some 21,566 patients were diagnosed with esophageal cancer of whom 359 (1.7%) had cN3M0 disease. Median OS of these patients was 12.5 months (95% CI: 10.7-14.3). Median OS following chemoradiotherapy alone and neoadjuvant therapy plus surgery was 13.3 months (95% CI: 10.7-15.9) and 23.7 months (95% CI: 18.3-29.2), respectively. Of all patients who underwent esophagectomy, 391 (2.8%) had (y)pN3 disease, and median OS was 16.1 months (95% CI: 14.8-17.4). Twenty-one patients (5.4%) were correctly classified as cN3, and 3-year OS was 21%., Conclusion(s): Clinical staging appears to be difficult, apparently in patients with N3 esophageal cancer. Surgery seems to be of benefit to these patients. More research is required to address the ongoing challenges in clinical staging and the best neoadjuvant therapy., (© 2024 The Author(s). Published by S. Karger AG, Basel.)
- Published
- 2024
- Full Text
- View/download PDF
47. Results of a diagnostic imaging audit in a randomised clinical trial in rectal cancer highlight the importance of careful planning and quality control.
- Author
-
Prata I, Eriksson M, Krdzalic J, Kranenbarg EM, Roodvoets AGH, Beets-Tan R, van de Velde CJH, van Etten B, Hospers GAP, Glimelius B, Nilsson PJ, Marijnen CAM, Peeters KCMJ, and Blomqvist LK
- Abstract
Background: Magnetic resonance (MR) imaging is the modality used for baseline assessment of locally advanced rectal cancer (LARC) and restaging after neoadjuvant treatment. The overall audited quality of MR imaging in large multicentre trials on rectal cancer is so far not routinely reported., Materials and Methods: We collected MR images obtained within the Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation (RAPIDO) trial and performed an audit of the technical features of image acquisition. The required MR sequences and slice thickness stated in the RAPIDO protocol were used as a reference., Results: Out of 920 participants of the RAPIDO study, MR investigations of 668 and 623 patients in the baseline and restaging setting, respectively, were collected. Of these, 304/668 (45.5%) and 328/623 (52.6%) MR images, respectively, fulfilled the technical quality criteria. The main reason for non-compliance was exceeding slice thickness 238/668, 35.6% in the baseline setting and 162/623, 26.0% in the restaging setting. In 166/668, 24.9% and 168/623, 27.0% MR images in the baseline and restaging setting, respectively, one or more of the required pulse sequences were missing., Conclusion: Altogether, 49.0% of the MR images obtained within the RAPIDO trial fulfilled the image acquisition criteria required in the study protocol. High-quality MR imaging should be expected for the appropriate initial treatment and response evaluation of patients with LARC, and efforts should be made to maximise the quality of imaging in clinical trials and in clinical practice., Critical Relevance Statement: This audit highlights the importance of adherence to MR image acquisition criteria for rectal cancer, both in multicentre trials and in daily clinical practice. High-resolution images allow correct staging, treatment stratification and evaluation of response to neoadjuvant treatment., Key Points: - Complying to MR acquisition guidelines in multicentre trials is challenging. - Neglection on MR acquisition criteria leads to poor staging and treatment. - MR acquisition guidelines should be followed in trials and clinical practice. - Researchers should consider mandatory audits prior to study initiation., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
48. Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery: A 5-Year Follow-up of the RAPIDO Trial.
- Author
-
Dijkstra EA, Nilsson PJ, Hospers GAP, Bahadoer RR, Meershoek-Klein Kranenbarg E, Roodvoets AGH, Putter H, Berglund Å, Cervantes A, Crolla RMPH, Hendriks MP, Capdevila J, Edhemovic I, Marijnen CAM, van de Velde CJH, Glimelius B, and van Etten B
- Subjects
- Humans, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Chemoradiotherapy, Follow-Up Studies, Neoadjuvant Therapy, Neoplasm Recurrence, Local pathology, Neoplasm Staging, Rectal Neoplasms pathology
- Abstract
Objective: To analyze risk and patterns of locoregional failure (LRF) in patients of the RAPIDO trial at 5 years., Background: Multimodality treatment improves local control in rectal cancer. Total neoadjuvant treatment (TNT) aims to improve systemic control while local control is maintained. At 3 years, LRF rate was comparable between TNT and chemoradiotherapy in the RAPIDO trial., Methods: A total of 920 patients were randomized between an experimental (EXP, short-course radiotherapy, chemotherapy, and surgery) and a standard-care group (STD, chemoradiotherapy, surgery, and optional postoperative chemotherapy). LRFs, including early LRF (no resection except for organ preservation/R2 resection) and locoregional recurrence (LRR) after an R0/R1 resection, were analyzed., Results: Totally, 460 EXP and 446 STD patients were eligible. At 5.6 years (median follow-up), LRF was detected in 54/460 (12%) and 36/446 (8%) patients in the EXP and STD groups, respectively ( P =0.07), in which EXP patients were more often treated with 3-dimensional-conformed radiotherapy ( P =0.029). In the EXP group, LRR was detected more often [44/431 (10%) vs. 26/428 (6%); P =0.027], with more often a breached mesorectum (9/44 (21%) vs. 1/26 (4); P =0.048). The EXP treatment, enlarged lateral lymph nodes, positive circumferential resection margin, tumor deposits, and node positivity at pathology were the significant predictors for developing LRR. Location of the LRRs was similar between groups. Overall survival after LRF was comparable [hazard ratio: 0.76 (95% CI, 0.46-1.26); P =0.29]., Conclusions: The EXP treatment was associated with an increased risk of LRR, whereas the reduction in disease-related treatment failure and distant metastases remained after 5 years. Further refinement of the TNT in rectal cancer is mandated., Competing Interests: P.J.N. reports honoraria from Ethicon, Johnson & Johnson, and Amgen. GAPH reports consulting fees from Roche, MSD, Amgen, and Novartis; consulting fees and research support to their institution from Bristol Myers Squibb; and research support to their institution from Seerave Foundation. A.G.H.R. and C.J.H.v.d.V. were partially funded by the EU’s Horizon 2020 research and innovation program under a Marie SkłodowskaCurie grant award (H2020MSCAITN2019, grant agreement number 857894; project acronym: CAST). M.P.H. reports consulting fees from MSD. J.C. reports consulting fees, travel expenses, and research support to their institution from Pfizer, Ipsen, and Eisai; consulting fees and research support to their institution from Bayer, Novartis, and Advanced Accelerator Applications; consulting fees from Sanofi, Exelixis, and Merck Serono; and research support to their institution from AstraZeneca. B.G. reports research support from the Swedish Cancer Society. The remaining authors report no conflicts of interest., (Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2023
- Full Text
- View/download PDF
49. Local recurrence in primary localised resected gastrointestinal stromal tumours: A registry observational national cohort study including 912 patients.
- Author
-
Bleckman RF, Roets E, IJzerman NS, Mohammadi M, Bonenkamp HJJ, Gelderblom H, Mathijssen RHJ, Steeghs N, Reyners AKL, and van Etten B
- Subjects
- Humans, Cohort Studies, Retrospective Studies, Imatinib Mesylate therapeutic use, Registries, Neoplasm Recurrence, Local, Gastrointestinal Stromal Tumors drug therapy, Antineoplastic Agents therapeutic use
- Abstract
Background and Objectives: Previous literature showed a high risk of recurrence following surgical treatment in patients with gastrointestinal stromal tumours (GISTs). However, little is known about the patient- and treatment characteristics of local recurrences (LRs) in GIST patients. Therefore, this study aimed to better understand patterns of LR in surgically treated localised GIST and to describe treatment options based on our Dutch GIST Registry (DGR)., Methods: Data of primary surgically treated localised GIST between January 2009 until July 2021 were retrospectively retrieved from the DGR., Results: Of 1452 patients registered in the DGR, 912 patients were included in this study. Only 3.8% (35/912) of patients developed LR, including 20 patients with LR only and 15 patients with simultaneous LR and distant metastases (DM). Median time to LR was 30 (interquartile range 8-53) months from date of surgery. Eleven percent (100/912) of patients developed only DM. A total of 2.3% (6/259) of patients treated with adjuvant treatment developed an LR during adjuvant therapy. Seventy percent of patients with LR only (14/20) were treated with surgery (85.7% R0), which was mostly combined with systemic treatment., Conclusions: Patients with primary surgically treated localised GIST have a limited risk of developing recurrence. Fifteen percent developed recurrence, of which one quarter developed an LR. Therefore, less intensified follow-up schedules could be considered, especially during treatment with adjuvant imatinib. In patients with LR only, potentially curative treatment strategies, including surgical (re-)resection, are often possible as treatment for LR., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: This work was supported by a research grant for the Dutch GIST Registry, which was received from Novartis (3017/13), Pfizer (WI189378), Bayer (2013-MED-12005) and Deciphera (4EE9EEC-7F19-484D-86A4-646CFE0950A5). These funding sources did not have any involvement in the conduction of this research., (Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
50. Risk and location of distant metastases in patients with locally advanced rectal cancer after total neoadjuvant treatment or chemoradiotherapy in the RAPIDO trial.
- Author
-
Bahadoer RR, Hospers GAP, Marijnen CAM, Peeters KCMJ, Putter H, Dijkstra EA, Kranenbarg EM, Roodvoets AGH, van Etten B, Nilsson PJ, Glimelius B, and van de Velde CJH
- Subjects
- Humans, Neoadjuvant Therapy, Neoplasm Staging, Chemoradiotherapy, Rectum pathology, Neoplasm Recurrence, Local pathology, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Rectal Neoplasms pathology, Neoplasms, Second Primary pathology
- Abstract
Introduction: Although optimising rectal cancer treatment has reduced local recurrence rates, many patients develop distant metastases (DM). The current study investigated whether a total neoadjuvant treatment strategy influences the development, location, and timing of metastases in patients diagnosed with high-risk locally advanced rectal cancer included in the Rectal cancer And Pre-operative Induction therapy followed by Dedicated Operation (RAPIDO) trial., Material and Methods: Patients were randomly assigned to short-course radiotherapy followed by 18 weeks of CAPOX or FOLFOX4 before surgery (EXP), or long-course chemoradiotherapy with optional postoperative chemotherapy (SC-G). Assessments for metastatic disease were performed pre- and post-treatment, during surgery, and 6, 12, 24, 36, and 60 months postoperatively. From randomisation, differences in the occurrence of DM and first site of metastasis were evaluated., Results: In total, 462 patients were evaluated in the EXP and 450 patients in the SC-G groups. The cumulative probability of DM at 5 years after randomisation was 23% [95% CI 19-27] and 30% [95% CI 26-35] (HR 0.72 [95% CI 0.56-0.93]; P = 0.011) in the EXP and SC-G, respectively. The median time to DM was 1.4 (EXP) and 1.3 years (SC-G). After diagnosis of DM, median survival was 2.6 years [95% CI 2.0-3.1] in the EXP and 3.2 years [95% CI 2.3-4.1] in the SC-G groups (HR 1.39 [95% CI 1.01-1.92]; P = 0.04). First occurrence of DM was most often in the lungs (60/462 [13%] EXP and 55/450 [12%] SC-G) or the liver (40/462 [9%] EXP and 69/450 [15%] SC-G). A hospital policy of postoperative chemotherapy did not influence the development of DM., Conclusions: Compared to long-course chemoradiotherapy, total neoadjuvant treatment with short-course radiotherapy and chemotherapy significantly decreased the occurrence of metastases, particularly liver metastases., Competing Interests: Conflict of interest statement The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Per Nilsson reports honoraria from Ethicon and Johnson & Johnson. Bengt Glimelius reports research support from the Swedish Cancer Society. Geke Hospers reports consulting fees from Roche, MSD, Amgen and Novartis; consulting fee and research support to their institution from Bristol-Myers Squibb; and research support to their institution from Seerave Foundation. All other authors have declared no conflicts of interest., (Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.